Indication

As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

Medicine details

Medicine name:
niraparib (Zejula)
SMC ID:
SMC2338
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
Q2 2021
SMC meeting date:
Q2 2021
Patient group submission deadline:
01 March 2021